Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8615845 | Clinical Lymphoma Myeloma and Leukemia | 2017 | 10 Pages |
Abstract
The incidence of CVEs and the frequency of asymptomatic PAD in this population was low, and CVEs were associated with cardiovascular risk factors. Aggressive risk factor modification and applying standard definitions for measuring cardiovascular outcomes might have contributed to the findings. Further prospective and adequately powered studies are needed to explore the effect of the cardiovascular risk profile on CVEs in CML patients taking nilotinib.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Nazanin Aghel, Jeffrey Howard Lipton, Eshetu G. Atenafu, Dennis Dong Hwan Kim, Diego Hernan Delgado,